Date: 2011-12-08
Type of information: Capital increase
Company: Agennix (Germany)
Investors: dievini Hopp BioTech (Germany) - shareholders
Amount: € 27.5 million
Funding type: capital increase
Planned used:
Others: Agennix AG has successfully completed its rights offering in which shareholders subscribed to all of the offered 9,319,504 new no-par value bearer shares by the end of the subscription period on December 6, 2011. The capital increase was a mixed capital increase of cash and contribution in kind. The contribution in kind involved the contribution by the Company’s major shareholder, dievini Hopp BioTech holding GmbH & Co. KG (dievini), of the € 15.0 million loan made to Agennix in July 2010, plus approximately € 1.2 million in accrued interest. As previously agreed, dievini exercised all of its subscription rights in the rights offering with respect to shares held by it, which represented the principal amount of the loan plus the accrued interest. As a result of this transaction, Agennix has no further obligations regarding this loan. In addition, dievini participated in the oversubscription offering. Following the completion of the offering, dievini will hold approximately 65% of shares outstanding in Agennix.
In this transaction, Agennix raised approximately € 11.3 million from subscriptions against cash and approximately € 16.2 million from the conversion to equity of an existing loan plus interest. The subscription price was € 2.95 per share, an approximately 4% discount to the XETRA closing price of € 3.06 per Agennix AG share on the Frankfurt Stock Exchange on November 16, 2011, the date of the announcement of the rights offering. The Management Board, with the approval of the Supervisory Board, has therefore resolved to increase the Company’s share capital from €41,937,776 to € 51,257,280 by issuing 9,319,504 new shares.
Therapeutic area: Cancer - Oncology
